ISF35 (rAd.CD40L)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ISF35 (rAd.CD40L), covering 2017-11-24 to 2017-11-24. Get the full timeline:
Most recent: Clinical Trial Update: Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma [Phase 1, Phase 2]